Immunic (IMUX) Short-Term Debt to Capital

Immunic, Inc. (IMUX) minimizes biological threats by developing a diverse range of oral treatments for chronic inflammation. This chart illustrates the price action of the asset, which currently stands at 0.00. The biotech firm is currently seeking a powerful Big Pharma partner to fund the final trials of its multiple sclerosis therapy. The business model relies on high scalability, where primary investments in science are followed by low-cost mass production of drugs.

This ratio measures the extent to which the capital structure depends on liabilities maturing within one year, determining the proportion of equity covered by short-term loans. By analyzing the trend of short-term liabilities relative to equity, an investor assesses the solvency of Immunic, Inc., which is critical for sustaining costly clinical trials of immunomodulators in the absence of current operating revenue.